Peer Review Committee for Cancer Drug Discovery (CDD)

Areas reviewed: Chemical studies dealing with the modification or development of drugs. Preclinical studies involving toxicity and effectiveness, and the development of drug delivery systems. Pharmacological studies, and studies involving nuclear magnetic resonance and crystallography, on the mechanisms of drug action, and the application of this information to drug design. Studies on the isolation, testing, and synthesis of natural therapeutic agents.

Eric B. Haura, MD, Chair
Moffitt Cancer Center/University of South Florida
Tampa, FL

Samy Meroueh, PhD, Vice Chair
Indiana University
Indianapolis, IN

Susan Clawson, Stakeholder
Braintree, MA

Joseph Contessa, MD, PhD
Yale University
New Haven, CT

M. Laird Forrest, PhD
University of Kansas
Lawrence, KS

M. Kyle Hadden, PhD
University of Connecticut
Storrs, CT

Geoffrey Hird, PhD
Liquidia Technologies, Inc.
Morrisville, NC

Mark Kester, PhD
University of Virginia/NanoSTAR Institute
Charlottesville, VA

Regan J. Thomson, PhD
Northwestern University, Evanston Campus
Evanston, IL

David N. Wald, MD, PhD
Case Western Reserve University
Cleveland, OH

Susan Wee, PhD
Bristol-Myers Squibb Company
Princeton, NJ